NCT04644770 2026-03-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT00643617 2023-05-09
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Accuray Incorporated
Phase NA Completed
NCT00643994 2023-05-09
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Accuray Incorporated
Phase NA Completed